Wegovy in pill form: what the UK release means for weight loss treatment

What exactly did the MHRA approve, and when did it happen?

The MHRA's approval on 11 June 2026 covered semaglutide tablets co-formulated with an absorption enhancer called SNAC. The tablet carries the same Wegovy brand name as the weekly injection and is made by Novo Nordisk. The UK was the first country in Europe to grant the licence, a detail worth noting because information from other countries (the US in particular) may describe different approval timelines or regulatory decisions that simply do not apply here.

The licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Those numbers match the injection's licensing thresholds fairly closely, though BMI alone never settles the question, a prescriber looks at the whole picture. If you want to understand whether either form of Wegovy fits your situation, this overview of Wegovy tablets for weight loss sets out the eligibility detail.

One thing the approval did not cover: NHS availability. At launch, Wegovy tablets require a private prescription because no NICE appraisal for the oral form existed yet. Wegovy tablet pricing for private patients is covered separately, including what a complete package should include.

How is taking a tablet different from using the injection?

The most obvious difference is the absence of a needle. The tablet is taken once daily, first thing in the morning, before any food, coffee or other medicines, swallowed whole with up to around 120 ml of plain water, then a minimum 30-minute wait before eating or drinking anything else. That morning routine is how the SNAC absorption enhancer does its job properly; skip or shorten it and the medicine may not absorb as intended.

Storage is simpler. Unlike the injection, which needs refrigeration between 2°C and 8°C, the tablet stays at room temperature. For anyone who travels regularly, or finds fridge logistics awkward, that matters practically. There is no pen to prime, no injection site to rotate, no sharps disposal to arrange.

The dose escalation still requires prescriber oversight. The schedule starts at 1.5 mg and moves through 4 mg and 9 mg before reaching the 25 mg maintenance dose, with at least a month at each level. Patients already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting from the beginning, and our page on Wegovy pill form covers the mechanics in more detail.

What does the trial evidence say about results?

The pivotal trial was OASIS 4, a phase-3 study involving 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, running over 64 weeks alongside lifestyle guidance. The results were published alongside the UK approval announcement by Novo Nordisk.

Average weight loss across all participants was approximately 13.6%, compared with around 2.4% on placebo. Among those who stayed fully adherent to the treatment through the trial, the average reached roughly 17%. That distinction matters: the headline figure applies to the whole group, adherence included. If you are wondering whether a pill form of Wegovy is now a genuine option, that page walks through those numbers in context alongside what they mean compared with the weekly injection's evidence base.

The most common side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea, vomiting and constipation appeared in around 74% of the oral semaglutide group (versus 42% on placebo), typically mild to moderate and settling as the body adjusted. That pattern mirrors the injection's profile, which the NHS semaglutide medicines page covers clearly. The MHRA approval announcement, published on GOV.UK, also confirms the side-effect profile referenced in prescribing documentation.

Is Wegovy in tablet form available through nume right now?

Wegovy tablets are a live part of the weight-loss treatments reviewed by the prescribers at our GPhC-registered online pharmacy. Every consultation is read personally by a GPhC-registered Independent Prescriber (not a decision algorithm) on the day it arrives. If tablets are clinically appropriate, orders placed before noon on a working day are dispatched the same day and delivered by DPD the next working day, in a plain unbranded box with full tracking on your phone.

Specific dose availability and which form suits you are confirmed at consultation, we do not list stock levels in advance, and that is intentional. Suitability depends on your health history, any medicines you are already taking, and what you are trying to achieve. If you have been on the injection and are thinking about switching, that conversation sits squarely with a prescriber rather than a webpage, and our guide to Wegovy in tablet form is a useful read before you do. Our clinical team is set up to handle exactly those questions. For a broader look at the options available, including full detail on the Wegovy pill, the treatment overview page is a sensible starting point before booking.